Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 14 | 2022 | 56 | 3.550 |
Why?
|
| Polyphenols | 4 | 2019 | 17 | 2.150 |
Why?
|
| Phaeophyta | 4 | 2017 | 5 | 2.000 |
Why?
|
| Pancreatic Neoplasms | 5 | 2019 | 505 | 1.490 |
Why?
|
| Signal Transduction | 9 | 2017 | 1339 | 1.370 |
Why?
|
| NF-kappa B | 7 | 2014 | 187 | 1.160 |
Why?
|
| N-Myc Proto-Oncogene Protein | 3 | 2022 | 11 | 1.070 |
Why?
|
| Gamma Rays | 3 | 2013 | 28 | 0.970 |
Why?
|
| Neoplastic Stem Cells | 4 | 2020 | 139 | 0.810 |
Why?
|
| Seaweed | 3 | 2019 | 6 | 0.810 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 1259 | 0.800 |
Why?
|
| Eye Proteins | 3 | 2019 | 197 | 0.770 |
Why?
|
| AC133 Antigen | 1 | 2020 | 7 | 0.730 |
Why?
|
| Antigens, CD34 | 1 | 2020 | 13 | 0.720 |
Why?
|
| Antigens, Surface | 1 | 2020 | 39 | 0.720 |
Why?
|
| Aquatic Organisms | 1 | 2019 | 5 | 0.670 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 123 | 0.660 |
Why?
|
| Carcinogenesis | 1 | 2019 | 79 | 0.640 |
Why?
|
| Disease Progression | 8 | 2020 | 450 | 0.610 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2014 | 244 | 0.600 |
Why?
|
| Bystander Effect | 2 | 2014 | 16 | 0.560 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 68 | 0.550 |
Why?
|
| Receptors, CXCR4 | 1 | 2017 | 27 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2022 | 443 | 0.540 |
Why?
|
| Apoptosis | 9 | 2019 | 737 | 0.540 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2013 | 32 | 0.540 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 62 | 0.480 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 656 | 0.480 |
Why?
|
| Autophagy | 1 | 2015 | 69 | 0.470 |
Why?
|
| Mice, Nude | 6 | 2019 | 312 | 0.460 |
Why?
|
| Transcription Factor RelA | 2 | 2014 | 21 | 0.460 |
Why?
|
| Humans | 25 | 2022 | 26856 | 0.450 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 9 | 0.440 |
Why?
|
| Animals | 16 | 2020 | 9954 | 0.430 |
Why?
|
| Benzylidene Compounds | 1 | 2013 | 29 | 0.430 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 35 | 0.420 |
Why?
|
| Piperidones | 1 | 2013 | 32 | 0.420 |
Why?
|
| Cell Nucleus | 1 | 2013 | 135 | 0.410 |
Why?
|
| Heart | 1 | 2013 | 219 | 0.410 |
Why?
|
| Cell Survival | 5 | 2019 | 393 | 0.400 |
Why?
|
| Curcumin | 1 | 2013 | 67 | 0.400 |
Why?
|
| Mice | 10 | 2019 | 4402 | 0.350 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 151 | 0.350 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 624 | 0.350 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2020 | 110 | 0.290 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 441 | 0.290 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 122 | 0.280 |
Why?
|
| Infant | 2 | 2020 | 963 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2017 | 250 | 0.270 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 30 | 0.270 |
Why?
|
| Prognosis | 5 | 2022 | 758 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 180 | 0.240 |
Why?
|
| Plant Extracts | 2 | 2017 | 62 | 0.230 |
Why?
|
| Radiation Tolerance | 2 | 2014 | 29 | 0.220 |
Why?
|
| Telomerase | 2 | 2013 | 37 | 0.210 |
Why?
|
| Aminoquinolines | 2 | 2013 | 11 | 0.210 |
Why?
|
| Aniline Compounds | 2 | 2013 | 22 | 0.200 |
Why?
|
| ErbB Receptors | 2 | 2013 | 96 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2016 | 278 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 143 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 453 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 152 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 2 | 2019 | 262 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2013 | 770 | 0.170 |
Why?
|
| Survival Rate | 1 | 2020 | 407 | 0.170 |
Why?
|
| Acetates | 1 | 2019 | 44 | 0.170 |
Why?
|
| Pediatrics | 1 | 2020 | 87 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 437 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2020 | 134 | 0.160 |
Why?
|
| Epithelial Cells | 2 | 2017 | 239 | 0.160 |
Why?
|
| Male | 5 | 2020 | 12866 | 0.160 |
Why?
|
| Adrenal Glands | 1 | 2017 | 21 | 0.150 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 88 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2017 | 36 | 0.150 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 239 | 0.140 |
Why?
|
| Oncogene Addiction | 1 | 2016 | 1 | 0.140 |
Why?
|
| Radiation | 1 | 2016 | 3 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2020 | 1090 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 33 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 129 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2017 | 196 | 0.130 |
Why?
|
| Transcription, Genetic | 2 | 2015 | 399 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 114 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 146 | 0.130 |
Why?
|
| Brain | 1 | 2021 | 697 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 310 | 0.120 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 60 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 110 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 323 | 0.120 |
Why?
|
| Cell Movement | 1 | 2017 | 353 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 309 | 0.120 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 25 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 148 | 0.120 |
Why?
|
| Child | 1 | 2020 | 2152 | 0.110 |
Why?
|
| Scattering, Radiation | 1 | 2014 | 28 | 0.110 |
Why?
|
| Retina | 1 | 2017 | 421 | 0.110 |
Why?
|
| Clone Cells | 1 | 2013 | 20 | 0.110 |
Why?
|
| Extracellular Space | 1 | 2013 | 25 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2013 | 645 | 0.110 |
Why?
|
| Immunoblotting | 1 | 2013 | 121 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2013 | 17 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 86 | 0.110 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2013 | 50 | 0.110 |
Why?
|
| Myocardium | 1 | 2013 | 171 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 1474 | 0.100 |
Why?
|
| Recurrence | 1 | 2013 | 316 | 0.100 |
Why?
|
| DNA Damage | 1 | 2013 | 147 | 0.100 |
Why?
|
| Wound Healing | 1 | 2013 | 113 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 3 | 0.100 |
Why?
|
| Linear Energy Transfer | 1 | 2011 | 4 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2013 | 282 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2013 | 559 | 0.100 |
Why?
|
| Heterografts | 3 | 2016 | 62 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2013 | 503 | 0.090 |
Why?
|
| Azadirachta | 1 | 2011 | 3 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2015 | 619 | 0.090 |
Why?
|
| Female | 2 | 2020 | 14462 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 1394 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 288 | 0.070 |
Why?
|
| Furosemide | 1 | 2007 | 7 | 0.070 |
Why?
|
| Diuretics | 1 | 2007 | 12 | 0.070 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 24 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2007 | 73 | 0.070 |
Why?
|
| Hypoxia | 1 | 2007 | 85 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 578 | 0.050 |
Why?
|
| Calgranulin B | 1 | 2022 | 17 | 0.050 |
Why?
|
| Quinolones | 1 | 2022 | 23 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 377 | 0.050 |
Why?
|
| Chemokines | 1 | 2022 | 73 | 0.050 |
Why?
|
| beta Catenin | 1 | 2022 | 62 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 73 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 50 | 0.050 |
Why?
|
| Intracellular Membranes | 1 | 2021 | 15 | 0.050 |
Why?
|
| DNA Fragmentation | 2 | 2014 | 17 | 0.050 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2021 | 29 | 0.050 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2021 | 33 | 0.040 |
Why?
|
| Cytokines | 1 | 2022 | 437 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 276 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2019 | 10 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 12 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 22 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 72 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 290 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 509 | 0.040 |
Why?
|
| Micronucleus, Germline | 1 | 2016 | 1 | 0.030 |
Why?
|
| Keratin-5 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 860 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2016 | 42 | 0.030 |
Why?
|
| Ions | 1 | 2016 | 18 | 0.030 |
Why?
|
| Oncogenes | 1 | 2016 | 34 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 81 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 98 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2015 | 5 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 20 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 36 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2007 | 537 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 59 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 37 | 0.030 |
Why?
|
| Transcriptome | 1 | 2016 | 198 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 277 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 225 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 395 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 7 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 457 | 0.030 |
Why?
|
| Computational Biology | 1 | 2015 | 150 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 40 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2014 | 53 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2014 | 50 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 68 | 0.030 |
Why?
|
| Rats | 2 | 2007 | 1536 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 194 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 262 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 110 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 239 | 0.020 |
Why?
|
| Plant Leaves | 1 | 2011 | 56 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 2017 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 2267 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2007 | 16 | 0.020 |
Why?
|
| Perfusion | 1 | 2007 | 43 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2007 | 31 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 1564 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 188 | 0.020 |
Why?
|
| Oxygen | 1 | 2007 | 218 | 0.020 |
Why?
|
| Inflammation | 1 | 2007 | 598 | 0.010 |
Why?
|